Literature DB >> 23137576

Safety of urate-lowering therapies: managing the risks to gain the benefits.

Robert T Keenan1.   

Abstract

Gout is a metabolic disorder of purine metabolism and uric acid elimination. Over time, acute gout can develop into a chronic, disabling arthropathy, often associated with multiple comorbidities. Gout patients have often been undertreated, partly because of the clinician's perceived risks of a therapy outweighing its potential benefits. The approval of new therapies to treat hyperuricemia in gout has led to a new understanding of gout management and medication safety regarding new and old therapies. This review focuses on potential safety issues of currently available urate-lowering therapies and outlines strategies to minimize risks so their benefits can be reached.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23137576     DOI: 10.1016/j.rdc.2012.08.008

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  4 in total

Review 1.  Tumor lysis syndrome: A clinical review.

Authors:  Aibek E Mirrakhimov; Prakruthi Voore; Maliha Khan; Alaa M Ali
Journal:  World J Crit Care Med       Date:  2015-05-04

Review 2.  New and Pipeline Drugs for Gout.

Authors:  Robert T Keenan; Naomi Schlesinger
Journal:  Curr Rheumatol Rep       Date:  2016-06       Impact factor: 4.592

Review 3.  Chinese herbal medicine for gout: a systematic review of randomized clinical trials.

Authors:  Xin-Xue Li; Mei Han; Yu-Yi Wang; Jian-Ping Liu
Journal:  Clin Rheumatol       Date:  2013-05-11       Impact factor: 2.980

Review 4.  Moving the Needle: Improving the Care of the Gout Patient.

Authors:  Jon Golenbiewski; Robert T Keenan
Journal:  Rheumatol Ther       Date:  2019-03-02
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.